Showing 2861-2870 of 3039 results for "".
- Ocuphire Pharma Raises Over $5 Million to Complete Late Phase 2 Clinical Trials for Ophthalmic Disordershttps://modernod.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/Ocuphire Pharma announced that it has closed on over $5 million of financing. Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol. Nyxol is a novel eye drop treatment for multiple front-of-the-eye disorders, including night vision distur
- Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.
- SparingVision Awarded €2.5 Million at EIC Accelerator Programhttps://modernod.com/news/sparingvision-awarded-e2-5-million-at-eic-accelerator-program/2476715/SparingVision announced that it has been awarded non-dilutive funding of €2.5 million to fund research into retinitis pigmentosa therapies. SparingVision submitted a winning proposal for the European EIC Accelerator (SME instrument phase 2) program. The funding will help speed up SparingVi
- Alcon Introduces Air Optix Plus HydraGlyde for Astigmatism Contact Lenseshttps://modernod.com/news/alcon-introduces-air-optix-plus-hydraglyde-for-astigmatism-contact-lenses/2479569/Alcon has launched Air Optix plus HydraGlyde for Astigmatism contact lenses in the United States. The newest addition to Alcon’s contact lens portfolio offers a combination of technologies that support long-lasting lens surface moisture and outstanding comfort to provide astigmatic patients a con
- Hoya Surgical Optics Obtains CE Mark for Nanex multiSert+ IOL Delivery Systemhttps://modernod.com/news/hoya-surgical-optics-obtained-ce-mark-for-nanex-multisert-iol-delivery-system/2476708/Hoya Surgical Optics has obtained CE Mark for Nanex multiSert+, which consists of a a new IOL delivered in a first-of-its kind preloaded delivery system, according to a company news release. The 1.62 mm injector tip of multiSert+ is the world’s smallest nozzle size in
- Low-Cost Retinal Scanner Could Help Prevent Blindness Worldwidehttps://modernod.com/news/low-cost-retinal-scanner-could-help-prevent-blindness-worldwide/2476705/Biomedical engineers at Duke University have developed a low-cost, portable optical coherence tomography (OCT) scanner that promises to bring the vision-saving technology to underserved regions throughout the United States and abroad, according to a university news release. Thanks to a red
- Oxurion NV Reports Topline Phase 1 Results with THR-149 for the treatment of DMEhttps://modernod.com/news/oxurion-nv-reports-topline-phase-1-results-with-thr-149-for-the-treatment-of-dme/2476706/Oxurion NV reported positive topline data from a phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). THR-149 has been developed in partnership with Bicycle Therapeutics. Oxurion holds the exclusive license to the PKal
- DORC Announces FDA Acceptance of Orphan NDA for Brilliant Blue G Ophthalmic Solutionhttps://modernod.com/news/dorc-announces-fda-acceptance-of-orphan-nda-for-brilliant-blue-g-ophthalmic-solution/2476701/DORC has announced that it has received notification from the FDA that their new drug application (NDA) for Brilliant Blue G ophthalmic solution has been accepted for review. The proposed indication for Brillia
- AlpineInvestors to Make Strategic Growth Investments in Ohio Eye Care Businesseshttps://modernod.com/news/alpineinvestors-to-make-strategic-growth-investments-in-ohio-eye-care-businesses/2476694/Private equity firm Alpine Investors has invested in Ohio-based eye care business, Northeast Ohio Eye Surgeons (NEOES), including its subsidiary business, Ohio Eye Care Consultants (OECC). The two companies will together form a new ophthalmology platform for Alpine, and will continue to operate i
- Ocular Therapeutix Receives FDA Approval of Supplemental NDA for Dextenza for Postoperative Ocular Inflammationhttps://modernod.com/news/ocular-therapeutix-receives-fda-approval-of-supplemental-nda-for-dextenza-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery/2476680/Ocular Therapeutix announced the FDA approved a supplemental new drug application (NDA) for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication. With the approval of the supplemental NDA, Dextenza is now approved for the treatment of b